A.A. reports research funding from Abbvi, Adaptive Biotech, and advisory role for Bristol-Myers Squibb, Karyopharm Therapeutics. H.H. reports consulting or advisory role for Janssen, Bristol-Myers Squibb, Sanofi; Speakers’ bureau for Sanofi, GlaxoSmithKline, and Karyopharm. D.K.H. reports research funding from Bristol-Myers Squibb, Janssen, Karyopharm, International Myeloma Society Young Investigator Award, and the Pentecost Family Myeloma Research Center and Adaptive Biotech and consulting or advisory role for Bristol-Myers Squibb, Janssen, Karyopharm and Pfizer, and member of the Bristol-Myers Squibb IMW Ide-Cel Academic Advisory Board, Bristol-Myers Squibb Multiple Myeloma ASH Steering Committee, and Multiple Myeloma Pfizer Advisory Board, and received net honoraria from OncLive and Survivorship. S.S. reports consulting or advisory role for Janssen, Bristol-Myers Squibb, Magenta Therapeutics, Sanofi, Takeda, Pfizer and Legend Biotech; Research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Bristol-Myers Squibb and Novartis. C.A report advisory role for Psomagen, and consulting for PPD Global, LSK Global, IAVIA, Advarra, Syneos Health. L.C.P. reports research funding from Bristol-Myers Squibb and Karyopharm. C.L.F. reports honoraria/consulting BMS, Seattle Genetics, Celgene, Abbvie, Sanofi, Incyte, Amgen, and ONK therapeutics & Janssen; and has research funding from BMS, Janssen and Roche/Genentech. O.C.P. reports payment on speaker bureaus from Adaptive Biotechnologies. S.A. reports honoraria from Janssen; Research funding from GlaxoSmithKline, Amgen, Karyopharm Therapeutics, Janssen, Bristol-Myers Squibb; Honoraria from Janssen. P.M.V. reports consulting or advisory role for Oncopeptides, Abbvie/Genentech, Karyopharm Therapeutics, Bristol-Myers Squibb, Secura Bio, Pfizer, Sanofi, Janssen, GlaxoSmithKline; Research funding from Abbvie, Janssen, GlaxoSmithKline, and TeneoBio; Travel, accommodations, and expenses from Sanofi, and involvement on a Data Safety and Monitoring Committee for Sanofi. L.S reports consulting or advisory role for Janssen. J.P.M. reports consultancy fees and honoraria from Magenta Therapeutics, Novartis, Bristol Myers Squibb, Juno Therapeutics, Kite, CRISPR Therapeutics, Nektar, and Allovir, reports honoraria from Sana, reports payment on speaker bureaus from Bristol Myers Squibb, Kite, and Allovir, and research funding from Magenta Therapeutics, Juno Therapeutics, Kite, Orca Bio, and Allovir. G.S. reports speaker bureau payment from Kite/Gilead. D.W.S. reports consulting or advisory role for Sanofi, GlaxoSmithKline, Janssen, Pfizer, Abbvie, Arcellx and BiolineRx; Research funding from Janssen, BioLineRx, Sanofi, Bristol-Myers Squibb, Amgen, Pfizer, Arcellx and Gilead Sciences. G.K. reports consulting or advisory committees for Bristol Myers Squibb, Cellectar, Sanofi, Janssen, and Arcellx, and research funding from Bristol Myers Squibb, Janssen, and Arcellx. C.J.F. reports payment from participation on an advisory board from Sanofi, and currently holds equity in a publicly traded company, Affimed. M.R.G. reports consulting for Boxer Capital, LLC. S.G. reports consultancy fees from BMS, Janssen, Sanofi, Meditope Biosciences, and research funding from BMS, Ipsen, Adaptive Biothechnology, and speaker bureau payment from Janssen, Adaptive Biotech. O.N reports membership on an entity’s Board of Directors or advisory committees from Bristol Myers Squibb, Karyopharm, GPCR Therapeutics, Adaptive Biotechnologies, GSK, and Janssen, and reports research funding from Takeda and Janssen. F.L.L reports a scientific advisory role for A2, Allogene, Amgen, Bluebird Bio, BMS/Celgene, Calibr, Cellular Biomedicine Group, GammaDelta Therapeutics, Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Takeda, Wugen, Umoja; research funding from Kite Pharma (Institutional), Allogene (Institutional), Novartis (Institutional), Blue-Bird Bio (Institutional), CERo Therapeutics (Institutional), and BMS (Institutional); patents, royalties, and other intellectual property including several patents held by the institution in his name (unlicensed) in the field of cellular immunotherapy; consulting roles for Cowen, EcoR1, Emerging Therapy Solutions, and Gerson Lehrman Group (GLG); and education or editorial activity for Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, and Society of Immunotherapy of Cancer. K.K.P reports consulting or advisory role for Bristol-Myers Squibb, Janssen, Pfizer, Arcellx, and Karyopharm Therapeutics; Research funding from Bristol-Myers Squibb, Poseida Therapeutics, Takeda, Janssen, Cellectis, Nektar, Abbvie/Genentech, Precision Biosciences, and Allogene Therapeutics; Travel, accommodations, and expenses from Bristol-Myers Squibb. J.K. reports honoraria from OncLive. L.A.D. Jr reports honoraria and membership on an entity’s Board of Directors or advisory committees for Bristol Myers Squibb, Celgene, GSK, AbbVie, Pharmacyclics, Karyopharm, Janssen, Prothena, Sanofi, Beigene, Cellectar, and Amgen. Y.L. reports consultancy fees from Janssen, Juno, Vineti, Kite/Gilead, Novartis, Legend, Sorrento, Gamida Cell, Celgene, Bluebird Bio, and research funding from Janssen, Kite/Gilead, Merck, Celgene, Bluebird Bio, and Takeda. Remaining authors with no potential conflicts of interest.

This multi-center study was approved by the respective institutions’ Institutional Review Board.